Shares of NYSE LLY traded up $10.29 on Wednesday, reaching $921.35. 1,329,631 shares of the company’s stock traded hands, compared to its average volume of 3,108,473. The company has a market ...

Its primary revenue drivers are the diabetes drugs Humalog (1996) and Trulicity (2014). Since the beginning of the year, one insider made 24 sales of Eli Lilly shares. One of the transactions was ...

and this PFS benefit was consistent across key subgroups, including patients who received prior venetoclax. Jacob Van Naarden, executive vice president and president of Lilly Oncology, said: “We are ...

Weekly GLP-1s from Eli Lilly (Trulicity) and GlaxoSmithKline (Tanzeum) also compete with Bydureon, and cardiovascular outcomes trials are ongoing. At this year’s European Association for the ...

This growth was primarily driven by the performance of key products such as Mounjaro, Zepbound, and Verzenio, offset partially by Trulicity. Eli Lilly's clinical development pipeline remains robust, ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...

Eli Lilly said Wednesday it will invest $27 billion to build four new manufacturing plants in the United States as the pharmaceutical giant grapples with the threat of drug import duties from the ...

Eli Lilly plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S. The drugmaker, which had committed to $23 billion in domestic investments from 2020 ...